Atossa Therapeutics Inc (ATOS)

Apr 22, 2025

Atossa Therapeutics announces issuance of U.S. patent - MSN

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics (ATOS) Secures New U.S. Patent for (Z)-endoxifen Formulations - GuruFocus

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics secures new patent for breast cancer treatment - Investing.com

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics (ATOS) Secures Patent for New (Z)-endoxifen Formulation | ATOS Stock News - GuruFocus

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics secures new patent for breast cancer treatment By Investing.com - Investing.com India

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - The Manila Times

Apr 22, 2025

Apr 22, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus

Apr 22, 2025

Apr 22, 2025

New Patent Strengthens Atossa's Breast Cancer Drug Portfolio: What This Means for Treatment Innovation - Stock Titan

Apr 22, 2025

Apr 22, 2025

Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World

Apr 22, 2025

Apr 11, 2025

Atossa Therapeutics (ATOS) Partners with Nona Biosciences to Adv - GuruFocus

Apr 11, 2025

Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Nex - GuruFocus

Apr 10, 2025

Apr 10, 2025

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - The Manila Times

Apr 10, 2025

Apr 10, 2025

Revolutionary Breast Cancer Treatment Alliance: Next-Gen Antibody Platform Powers New Research Initiative - Stock Titan

Apr 10, 2025

Apr 08, 2025

Atossa Therapeutics (NASDAQ:ATOS) & Pharming Group (OTCMKTS:PHGUF) Critical Comparison - Defense World

Apr 08, 2025

Apr 07, 2025

Atossa Therapeutics says Intas Pharmaceuticals Filed Petition For Post Grant Review Against Co- SEC Filing - marketscreener.com

Apr 07, 2025

Apr 03, 2025

Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN

Apr 03, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Apr 02, 2025

Mar 31, 2025

Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World

Mar 31, 2025

Mar 29, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 29, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada

Mar 29, 2025

Mar 29, 2025

Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World

Mar 29, 2025

Mar 28, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India

Mar 28, 2025

Mar 28, 2025

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 26, 2025

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo

Mar 26, 2025

Mar 26, 2025

Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 26, 2025

Mar 26, 2025

Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 26, 2025

Mar 25, 2025

Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks

Mar 25, 2025

Mar 25, 2025

Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025

Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025

Mar 23, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World

Mar 23, 2025

Mar 21, 2025

Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 20, 2025

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 20, 2025

Mar 20, 2025

Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 20, 2025

Mar 20, 2025

Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan

Mar 20, 2025

Mar 15, 2025

Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright - The AM Reporter

Mar 15, 2025

Mar 14, 2025

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

Mar 14, 2025

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times

Mar 11, 2025

Mar 11, 2025

Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan

Mar 11, 2025

Mar 11, 2025

Atossa targets metastatic breast cancer with (Z)-endoxifen - Investing.com

Mar 11, 2025

Mar 04, 2025

Atossa Genetics stock hits 52-week low at $0.72 - Investing.com

Mar 04, 2025

Feb 25, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com India

Feb 25, 2025